PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 15994321-4 2005 LPL significantly suppressed TNF-alpha-induced gene expression, and this suppression was reversed by tetrahydrolipstatin and heparinase. Orlistat 101-120 lipoprotein lipase Homo sapiens 0-3 16293890-4 2006 LPL stimulated this process through its action on VLDL lipolysis, because it was abolished by tetrahydrolipstatin. Orlistat 94-113 lipoprotein lipase Homo sapiens 0-3 9254059-6 1997 Addition of tetrahydrolipstatin (THL, an LPL active-site inhibitor) to HTG-VLDL + LPL, inhibited the cellular increase in both CE and TG by greater than 90%. Orlistat 12-31 lipoprotein lipase Homo sapiens 41-44 12573449-6 2003 Specific inhibition (90%) of the lipolytic activity of endogenous LPL by tetrahydrolipstatin (THL) in the presence of VLDL-1 or VLDL-2 resulted in marked reduction in cellular loading of both triglycerides (-89%, P=0.008, and -89%, P=0.015, respectively) and free cholesterol (-76%, P=0.02, and -55%, P=0.06 respectively). Orlistat 73-92 lipoprotein lipase Homo sapiens 66-69 12573449-6 2003 Specific inhibition (90%) of the lipolytic activity of endogenous LPL by tetrahydrolipstatin (THL) in the presence of VLDL-1 or VLDL-2 resulted in marked reduction in cellular loading of both triglycerides (-89%, P=0.008, and -89%, P=0.015, respectively) and free cholesterol (-76%, P=0.02, and -55%, P=0.06 respectively). Orlistat 94-97 lipoprotein lipase Homo sapiens 66-69 12137195-6 2002 The lytic effect of the LPL-Ps preparation could be inhibited by tetrahydrolipstatin. Orlistat 65-84 lipoprotein lipase Homo sapiens 24-27 9450109-0 1997 Inhibition of lipoprotein lipase activity by tetrahydrolipstatin. Orlistat 45-64 lipoprotein lipase Homo sapiens 14-32 14703506-6 2004 Tetrahydrolipstatin (LPL inhibitor) diminished baseline, ASP-, and insulin-stimulated in situ LPL activity, resulting in [(3)H]TG accumulation (P < 0.0001). Orlistat 0-19 lipoprotein lipase Homo sapiens 21-24 14703506-6 2004 Tetrahydrolipstatin (LPL inhibitor) diminished baseline, ASP-, and insulin-stimulated in situ LPL activity, resulting in [(3)H]TG accumulation (P < 0.0001). Orlistat 0-19 lipoprotein lipase Homo sapiens 94-97 9502759-3 1998 Density gradient analysis revealed that most of the secreted heart lipoproteins were LDLs, even when the labeling experiments were performed in the presence of tetrahydrolipstatin, an inhibitor of lipoprotein lipase. Orlistat 160-179 lipoprotein lipase Homo sapiens 197-215 9254059-6 1997 Addition of tetrahydrolipstatin (THL, an LPL active-site inhibitor) to HTG-VLDL + LPL, inhibited the cellular increase in both CE and TG by greater than 90%. Orlistat 12-31 lipoprotein lipase Homo sapiens 82-85 9254059-6 1997 Addition of tetrahydrolipstatin (THL, an LPL active-site inhibitor) to HTG-VLDL + LPL, inhibited the cellular increase in both CE and TG by greater than 90%. Orlistat 33-36 lipoprotein lipase Homo sapiens 41-44 9254059-6 1997 Addition of tetrahydrolipstatin (THL, an LPL active-site inhibitor) to HTG-VLDL + LPL, inhibited the cellular increase in both CE and TG by greater than 90%. Orlistat 33-36 lipoprotein lipase Homo sapiens 82-85 27342999-3 2016 METHODS: Tetrahydrolipstatin (THL), a potent inhibitor of serine lipases, was used to block the lipolytic activity of LPL, thereby preventing changes in the plasma lipoproteins due to ex vivo lipolysis. Orlistat 9-28 lipoprotein lipase Homo sapiens 118-121 8020477-0 1994 Interactions of lipoprotein lipase with the active-site inhibitor tetrahydrolipstatin (Orlistat). Orlistat 66-85 lipoprotein lipase Homo sapiens 16-34 8020477-0 1994 Interactions of lipoprotein lipase with the active-site inhibitor tetrahydrolipstatin (Orlistat). Orlistat 87-95 lipoprotein lipase Homo sapiens 16-34 8020477-1 1994 Lipoprotein lipase (LPL) was rapidly inactivated by low concentrations of the active-site inhibitor tetrahydrolipstatin (THL). Orlistat 100-119 lipoprotein lipase Homo sapiens 0-18 8020477-1 1994 Lipoprotein lipase (LPL) was rapidly inactivated by low concentrations of the active-site inhibitor tetrahydrolipstatin (THL). Orlistat 100-119 lipoprotein lipase Homo sapiens 20-23 8020477-1 1994 Lipoprotein lipase (LPL) was rapidly inactivated by low concentrations of the active-site inhibitor tetrahydrolipstatin (THL). Orlistat 121-124 lipoprotein lipase Homo sapiens 0-18 8020477-1 1994 Lipoprotein lipase (LPL) was rapidly inactivated by low concentrations of the active-site inhibitor tetrahydrolipstatin (THL). Orlistat 121-124 lipoprotein lipase Homo sapiens 20-23 8020477-4 1994 The fully inhibited enzyme had a ratio of THL/LPL of nearly 2, indicating that both subunits of the LPL homo-dimer bound THL. Orlistat 42-45 lipoprotein lipase Homo sapiens 100-103 8020477-4 1994 The fully inhibited enzyme had a ratio of THL/LPL of nearly 2, indicating that both subunits of the LPL homo-dimer bound THL. Orlistat 121-124 lipoprotein lipase Homo sapiens 100-103 8020477-8 1994 Sucrose density gradient centrifugation revealed that THL induces tetramerisation of LPL. Orlistat 54-57 lipoprotein lipase Homo sapiens 85-88 8020477-12 1994 It is suggested that THL induces local conformational changes in LPL, which may involve opening of the putative surface lid structure which covers the active-site. Orlistat 21-24 lipoprotein lipase Homo sapiens 65-68 27342999-3 2016 METHODS: Tetrahydrolipstatin (THL), a potent inhibitor of serine lipases, was used to block the lipolytic activity of LPL, thereby preventing changes in the plasma lipoproteins due to ex vivo lipolysis. Orlistat 30-33 lipoprotein lipase Homo sapiens 118-121 27342999-5 2016 RESULTS: When ex vivo lipolytic activity was inhibited by THL in the post-heparin plasma, majority of the LPL was found in the VLDL elution range, specifically in the RLP as inactive dimers. Orlistat 58-61 lipoprotein lipase Homo sapiens 106-109 27342999-7 2016 Furthermore, majority of the LPL in the pre-heparin plasma was found in the RLP as inactive form, with broadly diffused lipoprotein profiles in the presence and absence of THL. Orlistat 172-175 lipoprotein lipase Homo sapiens 29-32 22039521-8 2011 However, the lipase inhibitor tetrahydrolipstatin restored only a minor part of HCV infectivity, suggesting an important role of the LPL bridging function in the inhibition of infection. Orlistat 30-49 lipoprotein lipase Homo sapiens 133-136 23683858-6 2013 Inclusion of the lipoprotein lipase (LPL) inhibitor orlistat did not alter the effects of ppTGRL on chemokine production, and the expression of mRNA for LPL and other secreted lipases was unaffected by the lipoproteins. Orlistat 52-60 lipoprotein lipase Homo sapiens 37-40 19505770-5 2009 Orlistat also potently inhibits lipoprotein lipase, monoacylglycerol lipase and diacylglycerol lipase, which are also involved in AD causation. Orlistat 0-8 lipoprotein lipase Homo sapiens 32-50 20628023-7 2010 In the presence of Intralipid, the LPL hydrolytic inhibitor tetrahydrolipstatin blocked excess glucose retention in cellular TG but did not significantly decrease glucose disappearance in C2/LPL cells. Orlistat 60-79 lipoprotein lipase Homo sapiens 35-38 18698144-6 2008 Orlistat (tetrahydrolipstatin), a specific inhibitor of the lipoidolytic activity of endogenous LPL, and heparinase, which degrades cell-surface heparan sulfate proteoglycans, were also used to estimate the role of either the enzymolysis or "molecular bridge" actions of LPL in the uptake of VLDL. Orlistat 0-8 lipoprotein lipase Homo sapiens 96-99 18698144-6 2008 Orlistat (tetrahydrolipstatin), a specific inhibitor of the lipoidolytic activity of endogenous LPL, and heparinase, which degrades cell-surface heparan sulfate proteoglycans, were also used to estimate the role of either the enzymolysis or "molecular bridge" actions of LPL in the uptake of VLDL. Orlistat 0-8 lipoprotein lipase Homo sapiens 271-274 18698144-6 2008 Orlistat (tetrahydrolipstatin), a specific inhibitor of the lipoidolytic activity of endogenous LPL, and heparinase, which degrades cell-surface heparan sulfate proteoglycans, were also used to estimate the role of either the enzymolysis or "molecular bridge" actions of LPL in the uptake of VLDL. Orlistat 10-29 lipoprotein lipase Homo sapiens 96-99 17517063-7 2007 This effect is prevented by anti-LPL antibodies and by tetrahydrolipstatin (THL) a specific inhibitor of LPL enzymatic activity. Orlistat 55-74 lipoprotein lipase Homo sapiens 105-108 17517063-7 2007 This effect is prevented by anti-LPL antibodies and by tetrahydrolipstatin (THL) a specific inhibitor of LPL enzymatic activity. Orlistat 76-79 lipoprotein lipase Homo sapiens 105-108